<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAMPRAL- acamprosate calciumÂ tablet, delayed releaseÂ </strong><br>Carilion Materials Management<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use CAMPRAL safely and effectively.  See full prescribing information for CAMPRAL. CAMPRALÂ® (acamprosate calcium) Delayed-Release Tablets Initial U.S. Approval:  2004
        <br><br>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><ul class="Disc">
<li>CampralÂ® is indicated for the maintenance of abstinence from alcohol in patients with alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> who are abstinent at treatment initiation ( , ).
                                        <a href="#s1">1</a><a href="#s51">14</a>
</li>
<li>Treatment with Campral should be part of a comprehensive management program that includes psychosocial support ( ).
                                        <a href="#s1">1</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>Recommended dose: 666 mg (two 333 mg tablets) taken three times daily ( ).
                                        <a href="#s2">2</a>
</li>
<li>Dose reduction to one 333 mg tablet taken three times daily for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance 30-50 mL/min) ( ).
                                        <a href="#s3">2.1</a>
</li>
<li>Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) ( , , , , ).
                                        <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s9">5.1</a><a href="#s30">8.6</a><a href="#s36">12.3</a>
</li>
</ul></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Enteric-coated tablets, 333 mg ( ).
                                    <a href="#s4">3</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Campral is contraindicated in patients who previously have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to acamprosate calcium or any of its components ( ).
                                        <a href="#s6">4.1</a>
</li>
<li>Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> ( ).
                                        <a href="#s7">4.2</a>
</li>
</ul></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Dose reduction is required for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> ( ).
                                        <a href="#s9">5.1</a>
</li>
<li>Monitor patients for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> and prompt patients, families, and caregivers to report such symptoms to the health care provider ( ).
                                        <a href="#s10">5.2</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Common adverse events that occurred in any Campral treatment group at a rate of 3% or greater and greater than the placebo group in controlled clinical trials with spontaneously reported adverse events are:  <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">accidental injury</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> ( ).
                                    <a href="#s13">6.1</a> </p>
<p class="Highlighta">.
                                    <span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Forest Laboratories, Inc. at 1-800-678-1605, or FDA at 1-800-FDA-1088 or</span><span class="Bold Italics Underline">www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Campral should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus ( ).
                                        <a href="#s22">8.1</a>
</li>
<li>Nursing Mothers: Caution should be exercised when Campral is administered to a nursing woman ( ).
                                        <a href="#s27">8.3</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Dose reduction required for moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; contraindicated in severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> ( , , , , )
                                        <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s9">5.1</a><a href="#s30">8.6</a><a href="#s36">12.3</a>
</li>
</ul></div>
<div><div>
<div></div>
<div></div>
</div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div><div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosage in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h2><a href="#section-4.1" class="toc">4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Acamprosate Calcium</a></h2>
<h2><a href="#section-4.2" class="toc">4.2 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Suicidality and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Alcohol Withdrawal</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Information for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">CampralÂ® is indicated for the maintenance of abstinence from alcohol in patients with alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> who are abstinent at treatment initiation.  Treatment with Campral should be part of a comprehensive management program that includes psychosocial support.</p>
<p>The efficacy of Campral in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning Campral treatment.  The efficacy of Campral in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">The recommended dose of Campral is two 333 mg tablets (each dose should total 666 mg) taken three times daily. A lower dose may be effective in some patients.</p>
<p>Although dosing may be done without regard to meals, dosing with meals was employed during clinical trials and is suggested in those patients who regularly eat three meals daily.</p>
<p>Treatment with Campral should be initiated as soon as possible after the period of alcohol withdrawal, when the patient has achieved abstinence, and should be maintained if the patient relapses.  Campral should be used as part of a comprehensive psychosocial treatment program.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosage in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">For patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30-50 mL/min), a starting dose of one 333 mg tablet taken three times daily is recommended.  Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) [ and ].
                                    <span class="Italics">see Contraindications ( ), Warnings and Precautions ( ), Use in Specific Populations ( ),
                                        <a href="#s7">4.2</a><a href="#s9">5.1</a><a href="#s30">8.6</a></span><span class="Italics">Clinical Pharmacology ( )
                                        <a href="#s36">12.3</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Campral 333 mg tablets are enteric-coated, white, round, biconvex tablets, identified with â€œ333â€? debossed on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.1"></a><p></p>
<h2>4.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to Acamprosate Calcium</h2>
<p class="First">Campral is contraindicated in patients who previously have exhibited <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to acamprosate calcium or any of its components.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-4.2"></a><p></p>
<h2>4.2 Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) [ and ].
                                    <span class="Italics">see Dosage and Administration ( ), Warnings and Precautions ( ), Use in Specific Populations ( ),
                                        <a href="#s3">2.1</a><a href="#s9">5.1</a><a href="#s30">8.6</a></span><span class="Italics">Clinical Pharmacology ( )
                                        <a href="#s36">12.3</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s8"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Treatment with Campral in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30-50 mL/min) requires a dose reduction [ ].  Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) [ and ].
                                    <span class="Italics">see Dosage and Administration ( )
                                        <a href="#s3">2.1</a></span><span class="Italics">see Dosage and Administration ( ), Contraindications ( ), Use in Specific Populations ( ),
                                        <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s30">8.6</a></span><span class="Italics">Clinical Pharmacology ( )
                                        <a href="#s36">12.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Suicidality and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></h2>
<p class="First">In controlled clinical trials of Campral, adverse events of a suicidal nature (<span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">completed suicides</span>) were infrequent overall, but were more common in Campral-treated patients than in patients treated with placebo (1.4% vs. 0.5% in studies of 6 months or less; 2.4% vs. 0.8% in year-long studies). <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Completed suicides</span> occurred in 3 of 2272 (0.13%) patients in the pooled acamprosate group from all controlled studies and 2 of 1962 patients (0.10%) in the placebo group. Adverse events coded as "<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>" were reported at similar rates in Campral-treated and placebo-treated patients.  Although many of these events occurred in the context of alcohol relapse, and the interrelationship between alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and suicidality is well-recognized and complex, no consistent pattern of relationship between the clinical course of recovery from <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span> and the emergence of suicidality was identified.  Alcohol-dependent patients, including those patients being treated with Campral, should be monitored for the development of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidal thinking.  Families and caregivers of patients being treated with Campral should be alerted to the need to monitor patients for the emergence of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, and to report such symptoms to the patient's health care provider.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Alcohol Withdrawal</h2>
<p class="First">Use of Campral does not eliminate or diminish withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s12"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s13"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Clinically significant serious adverse reactions associated with Campral described elsewhere in labeling include suicidality and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute kidney failure</span> [s , and ].
                                    <span class="Italics">ee Warnings and Precautions ( )
                                        <a href="#s10">5.2</a></span><span class="Italics">Adverse Reactions ( )
                                        <a href="#s18">6.2</a></span></p>
<p>The adverse event data described below reflect the safety experience in over 7000 patients exposed to Campral for up to one year, including over 2000 Campral-exposed patients who participated in placebo-controlled trials.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Adverse Events Leading to Discontinuation</span></p>
<p>In placebo-controlled trials of 6 months or less, 8% of Campral-treated patients discontinued treatment due to an adverse event, as compared to 6% of patients treated with placebo.  In studies longer than 6 months, the discontinuation rate due to adverse events was 7% in both the placebo-treated and the Campral-treated patients.  Only <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was associated with the discontinuation of more than 1% of patients (2% of Campral-treated vs. 0.7% of placebo-treated patients).  Other events, including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, while accounting for discontinuation in less than 1% of patients, were nevertheless more commonly cited in association with discontinuation in Campral-treated patients than in placebo-treated patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Common Adverse Events Reported in Controlled Trials</span></p>
<p>Common adverse events were collected spontaneously in some controlled studies and using a checklist in other studies.  The overall profile of adverse events was similar using either method. shows those events that occurred in any Campral treatment group at a rate of 3% or greater and greater than the placebo group in controlled clinical trials with spontaneously reported adverse events. The reported frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed, without regard to the causal relationship of the events to the drug.
                                            <a href="#t1">Table 1</a></p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Events Occurring at a Rate of at Least 3% and Greater than Placebo in any Campral Treatment Group in Controlled Clinical Trials with Spontaneously Reported Adverse Events.</span></caption>
<col align="left" width="26.000%">
<col align="left" width="18.500%">
<col align="left" width="18.500%">
<col align="left" width="18.500%">
<col align="left" width="18.500%">
<thead>
<tr class="First">
<th class="Botrule Lrule Rrule Toprule" align="left" rowspan="2" valign="bottom"><span class="Bold">Body System/Preferred Term</span></th>
<th class="Botrule Rrule Toprule" align="center" colspan="4" valign="top"><span class="Bold">Number of Patients (%) with Events</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="center" valign="top"><span class="Bold">Campral 1332 mg/day
                                                            <br></span></th>
<th class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Campral 1998 mg/day
                                                            <br></span><span class="Sup">1</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom">
<span class="Bold">Campral Pooled
                                                            <br></span><span class="Sup">2</span>
</th>
<th class="Botrule Rrule" align="center" valign="bottom"><span class="Bold">Placebo</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5" valign="top"><p class="First Footnote">â€ *includes events coded as â€œfractureâ€? by sponsor; â€ â€ **includes events coded as â€œnervousnessâ€? by sponsor</p></td></tr>
<tr><td align="left" colspan="5" valign="top"><p class="First Footnote">includes 258 patients treated with  acamprosate calcium 2000 mg/day, using a different dosage strength and regimen.
                                                            <span class="Sup">1</span></p></td></tr>
<tr class="Last"><td align="left" colspan="5" valign="top"><p class="First Footnote">includes all patients in the first two columns as well as 83 patients treated with acamprosate calcium 3000 mg/day, using a different dosage strength and regimen.
                                                            <span class="Sup">2</span></p></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Number of patients in Treatment Group</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">397</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">1539</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">2019</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">1706</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Number (%) of patients with an AE</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">248 (62%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">910 (59%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">1231 (61%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">955 (56%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">121 (30%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">513 (33%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">685 (34%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">517 (30%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental Injury</span>*â€ </td>
<td class="Botrule Rrule" align="center" valign="top">17 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">44 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">70 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">52 (  3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td class="Botrule Rrule" align="center" valign="top">29 (  7%)</td>
<td class="Botrule Rrule" align="center" valign="top">79 (  5%)</td>
<td class="Botrule Rrule" align="center" valign="top">114 (  6%)</td>
<td class="Botrule Rrule" align="center" valign="top">93 (  5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">6 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">56 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">65 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">55 (  3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Digestive System</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">85 (21%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">440 (29%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">574 (28%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">344 (20%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Botrule Rrule" align="center" valign="top">20 (  5%)</td>
<td class="Botrule Rrule" align="center" valign="top">35 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">57 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">44 (  3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Botrule Rrule" align="center" valign="top">39 (10%)</td>
<td class="Botrule Rrule" align="center" valign="top">257 (17%)</td>
<td class="Botrule Rrule" align="center" valign="top">329 (16%)</td>
<td class="Botrule Rrule" align="center" valign="top">166 (10%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Botrule Rrule" align="center" valign="top">4 (  1%)</td>
<td class="Botrule Rrule" align="center" valign="top">55 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">63 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">28 (  2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="top">11 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">69 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">87 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">58 (  3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Nervous System</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">150 (38%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">417 (27%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">598 (30%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">500 (29%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â Anxietyâ€ â€ **</td>
<td class="Botrule Rrule" align="center" valign="top">32 (  8%)</td>
<td class="Botrule Rrule" align="center" valign="top">80 (  5%)</td>
<td class="Botrule Rrule" align="center" valign="top">118 (  6%)</td>
<td class="Botrule Rrule" align="center" valign="top">98 (  6%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Botrule Rrule" align="center" valign="top">33 (  8%)</td>
<td class="Botrule Rrule" align="center" valign="top">63 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">102 (  5%)</td>
<td class="Botrule Rrule" align="center" valign="top">87 (  5%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">15 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">49 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">67 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">44 (  3%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">13 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">23 (  1%)</td>
<td class="Botrule Rrule" align="center" valign="top">36 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">28 (  2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Botrule Rrule" align="center" valign="top">34 (  9%)</td>
<td class="Botrule Rrule" align="center" valign="top">94 (  6%)</td>
<td class="Botrule Rrule" align="center" valign="top">137 (  7%)</td>
<td class="Botrule Rrule" align="center" valign="top">121 (  7%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td class="Botrule Rrule" align="center" valign="top">11 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">29 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">40 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">34 (  2%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="Bold">Skin and Appendages</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">26 ( 7%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">150 (10%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">187 (  9%)</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">169 (10%)</span></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Rrule" align="center" valign="top">12 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">68 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">82 (  4%)</td>
<td class="Botrule Rrule" align="center" valign="top">58 (  3%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td class="Botrule Rrule" align="center" valign="top">11 (  3%)</td>
<td class="Botrule Rrule" align="center" valign="top">27 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">40 (  2%)</td>
<td class="Botrule Rrule" align="center" valign="top">39 (  2%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Concomitant Therapies</span></p>
<p>In clinical trials, the safety profile in subjects treated with Campral concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.  Patients taking Campral concomitantly with antidepressants more commonly reported both <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, compared with patients taking either medication alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Other Events Observed During the Premarketing Evaluation of Campral</span></p>
<p>Following is a list of terms that reflect treatment-emergent adverse events reported by patients treated with Campral in 20 clinical trials (4461 patients treated with Campral, 3526 of whom received the maximum recommended dose of 1998 mg/day for up to one year in duration).  This listing does not include those events already listed above; events for which a drug cause was considered remote; event terms which were so general as to be uninformative; and events reported only once which were not likely to be acutely life-threatening.</p>
<p>Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions:  frequent adverse events are those occurring in at least 1/100 patients (only those not already listed in the summary of adverse events in controlled trials appear in this listing); infrequent adverse events are those occurring in 1/100 to 1/1000 patients; rare events are those occurring in fewer than 1/1000 patients.</p>
<p>:  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">flu syndrome</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>; :  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4244894" conceptname="Intentional drug overdose">intentional overdose</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="199860" conceptname="Hernia of abdominal cavity">hernia</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">intentional injury</span>; :  <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">ascites</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>.
                                            <span class="Bold">Body as a Whole â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>; :  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, <span class="product-label-link" type="condition" conceptid="441644" conceptname="Varicose veins of legs in pregnancy and the puerperium">varicose vein</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarct</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>; :  <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4162038" conceptname="Occlusion of artery">arterial occlusion</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>.
                                            <span class="Bold">Cardiovascular System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>; :  <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function tests abnormal</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">liver cirrhosis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>; <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4057053" conceptname="Acute duodenal ulcer">duodenal ulcer</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulceration</span>, carcinoma of liver.
                                            <span class="Bold">Digestive System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p><span class="product-label-link" type="condition" conceptid="135772" conceptname="Goiter">goiter</span>, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>.
                                            <span class="Bold">Endocrine System â€“</span><span class="Italics">Rare:</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="434910" conceptname="Monocytosis">monocytosis</span>.
                                            <span class="Bold">Hemic and Lymphatic System â€“</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>â€“ <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; :  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased, SGPT increased, <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="436658" conceptname="Vitamin deficiency">avitaminosis</span>, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">bilirubinemia</span>; alkaline phosphatase increased, creatinine increased, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, lactic dehydrogenase increased.
                                            <span class="Bold">Metabolic and Nutritional Disorders â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>â€“ <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>; :  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.
                                            <span class="Bold">Musculoskeletal System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>â€“<span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">amnesia</span>, <span class="product-label-link" type="condition" conceptid="4131797" conceptname="Disturbance in thinking">thinking abnormal</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; :  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, withdrawal syndrome, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">apathy</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span>, <span class="product-label-link" type="condition" conceptid="373852" conceptname="Neuralgia">neuralgia</span>, <span class="product-label-link" type="condition" conceptid="4195585" conceptname="Hostile behavior">hostility</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">neurosis</span>, <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">abnormal dreams</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypesthesia</span>; :  <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcohol craving</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span>, <span class="product-label-link" type="condition" conceptid="4247265" conceptname="Muscle twitch">twitching</span>, <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">depersonalization</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">increased salivation</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>.
                                            <span class="Bold">Nervous System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough increased</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>; :  <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>; <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngismus</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolus</span>.
                                            <span class="Bold">Respiratory System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>; :  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>; <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">psoriasis</span>.
                                            <span class="Bold">Skin and Appendages â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span>; :  <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="376981" conceptname="Amblyopia">amblyopia</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">deafness</span>; <span class="product-label-link" type="condition" conceptid="438738" conceptname="Panophthalmitis">ophthalmitis</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>.
                                            <span class="Bold">Special Senses â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
<p>:  <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>; â€“ <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual function abnormal</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span>; <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney calculus</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">abnormal ejaculation</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">nocturia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>.
                                            <span class="Bold">Urogenital System â€“</span><span class="Italics">Frequent</span><span class="Italics">Infrequent</span><span class="Italics">Rare:</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of Campral.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Bold">Serious Adverse Events Observed During the Non-US Postmarketing Evaluation of Campral (acamprosate calcium)</span></p>
<p>The serious adverse event of <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute kidney failure</span> has been reported to be temporally associated with Campral treatment in at least 3 patients and is not described elsewhere in the labeling.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s20"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Acamprosate does not affect the pharmacokinetics of alcohol. The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ ].
                            <span class="Italics">see Clinical Pharmacology ( )
                                <a href="#s36">12.3</a></span></p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s21"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s22"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<div class="Section" data-sectionCode="34077-8">
<a name="s24"></a><a name="section-8.1.1.1"></a><p></p>
<p class="First">Acamprosate calcium has been shown to be teratogenic in rats when given in doses that are approximately equal to the human dose (on a mg/m basis) and in rabbits when given in doses that are approximately 3 times the human dose (on a mg/m basis).  Acamprosate calcium produced a dose-related increase in the number of fetuses with malformations in rats at oral doses of 300 mg/kg/day or greater (approximately equal to the maximum recommended human daily (MRHD) oral dose on a mg/m basis).  The malformations included <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span>, malformed iris, retinal <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span>, and retroesophageal subclavian artery.  No findings were observed at an oral dose of 50 mg/kg/day (approximately one-fifth the MRHD oral dose on a mg/m basis).  An increased incidence of <span class="product-label-link" type="condition" conceptid="433811" conceptname="Hydronephrosis">hydronephrosis</span> was also noted in Burgundy Tawny rabbits at oral doses of 400 mg/kg/day or greater (approximately 3 times the MRHD oral dose on a mg/m basis).  No developmental effects were observed in New Zealand white rabbits at oral doses up to 1000 mg/kg/day (approximately 8 times the MRHD oral dose on a mg/m basis).  The findings in animals should be considered in relation to known adverse developmental effects of ethyl alcohol, which include the characteristics of fetal alcohol syndrome (craniofacial <span class="product-label-link" type="condition" conceptid="4080891" conceptname="Dysmorphism">dysmorphism</span>, intrauterine and postnatal <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, retarded psychomotor and intellectual development) and milder forms of neurological and behavioral disorders in humans.  There are no adequate and well controlled studies in pregnant women.  Campral should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
                                                    <span class="Bold">Teratogenic effects:</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s25"></a><a name="section-8.1.1.2"></a><p></p>
<p class="First">A study conducted in pregnant mice that were administered acamprosate calcium by the oral route starting on Day 15 of gestation through the end of lactation on postnatal day 28 demonstrated an increased incidence of still-born fetuses at doses of 960 mg/kg/day or greater (approximately 2 times the MRHD oral dose on a mg/m basis).  No effects were observed at a dose of 320 mg/kg/day (approximately one-half the MRHD dose on a mg/m basis).
                                                    <span class="Bold">Nonteratogenic effects:</span><span class="Sup">2</span><span class="Sup">2</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s26"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The potential for Campral to affect the duration of labor and delivery is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s27"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">In animal studies, acamprosate was excreted in the milk of lactating rats dosed orally with acamprosate calcium.  The concentration of acamprosate in milk compared to blood was 1.3:1.  It is not known whether acamprosate is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when Campral is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s28"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and efficacy of Campral have not been established in the pediatric population.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s29"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Forty-one of the 4234 patients in double-blind, placebo-controlled, clinical trials of Campral were 65 years of age or older, while none were 75 years of age or over.  There were too few patients in the â‰¥65 age group to evaluate any differences in safety or effectiveness for geriatric patients compared to younger patients.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function and ].
                                    <span class="Italics">[see Clinical Pharmacology ( ), Adverse Reactions ( ),
                                        <a href="#s36">12.3</a><a href="#s13">6.1</a></span><span class="Italics">Dosage and Administration ( )
                                        <a href="#s3">2.1</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) [s and ].
                                    <span class="Italics">ee Dosage and Administration ( ), Contraindications ( ), Warnings and Precautions ( ),
                                        <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s9">5.1</a></span><span class="Italics">Clinical Pharmacology ( )
                                        <a href="#s36">12.3</a></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s31"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">In all reported cases of acute overdosage with Campral (total reported doses of up to 56 grams of acamprosate calcium), the only symptom that could be reasonably associated with Campral was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">Hypercalcemia</span> has not been reported in cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>.  A risk of <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> should be considered in chronic overdosage only. Treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> should be symptomatic and supportive.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s32"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Campral (acamprosate calcium) is supplied in an enteric-coated tablet for oral administration.  Acamprosate calcium is a synthetic compound with a chemical structure similar to that of the endogenous amino acid homotaurine, which is a structural analogue of the amino acid neurotransmitter Î³-aminobutyric acid and the amino acid neuromodulator taurine.  Its chemical name is calcium acetylaminopropane sulfonate. Its chemical formula is C H N O S Ca and molecular weight is 400.48.  Its structural formula is:
                            <span class="Sub">10</span><span class="Sub">20</span><span class="Sub">2</span><span class="Sub">8</span><span class="Sub">2</span></p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe6f754f-62b4-4c86-805d-221332409516&amp;name=cam01-0008-01.jpg">
</div>
<p>Acamprosate calcium is a white, odorless or nearly odorless powder. It is freely soluble in water, and practically insoluble in absolute ethanol and dichloromethane.</p>
<p>Each Campral tablet contains acamprosate calcium 333 mg, equivalent to 300 mg of acamprosate.  Inactive ingredients in Campral tablets include:  crospovidone, microcrystalline cellulose, magnesium silicate, sodium starch glycolate, colloidal anhydrous silica, magnesium stearate, talc, propylene glycol and Eudragit L 30 D or equivalent.  Sulfites were used in the synthesis of the drug substance and traces of residual sulfites may be present in the drug product.
                            <span class="Sup">Â®</span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s33"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s34"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. and studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
                                    <span class="Italics">In vitro</span><span class="Italics">in vivo</span></p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="s35"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.</p>
<p>The administration of acamprosate calcium is not associated with the development of tolerance or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in animal studies.  Campral did not produce any evidence of withdrawal symptoms in patients in clinical trials at therapeutic doses.  Post marketing data, collected retrospectively outside the U.S. have provided no evidence of Campral abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Campral is not known to cause alcohol <span class="product-label-link" type="condition" conceptid="4261542" conceptname="Aversion">aversion</span> and does not cause a disulfiram-like reaction as a result of ethanol ingestion.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s36"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>The absolute bioavailability of Campral after oral administration is about 11%.  Steady-state plasma concentrations of acamprosate are reached within 5 days of dosing.  Steady-state peak plasma concentrations after Campral doses of 2Â xÂ 333 mg tablets three times daily average 350Â ng/mL and occur at 3-8 hours post-dose.  Coadministration of Campral with food decreases bioavailability as measured by C and AUC, by approximately 42% and 23%, respectively.  The food effect on absorption is not clinically significant and no adjustment of dose is necessary.
                                            <span class="Sub">max</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s38"></a><a name="section-11.3.1.1"></a><p></p>
<p class="First"><span class="Italics">Distribution</span></p>
<p>The volume of distribution for acamprosate following intravenous administration is estimated to be 72-109 liters (approximately 1 L/kg).  Plasma protein binding of acamprosate is negligible.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.3.1.2"></a><p></p>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Acamprosate does not undergo metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.3.1.3"></a><p></p>
<p class="First"><span class="Italics">Elimination</span></p>
<p>After oral dosing of 2Â xÂ 333 mg of Campral, the terminal half-life ranges from approximately 20-33 hours.  Following oral administration of Campral, the major route of excretion is via the kidneys as acamprosate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.3.2.1"></a><p></p>
<p class="First">Campral does not exhibit any significant pharmacokinetic differences between male and female subjects.
                                                    <span class="Bold Italics">Gender:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3.2.2"></a><p></p>
<p class="First">The pharmacokinetics of Campral have not been evaluated in a geriatric population. However, since renal function diminishes in elderly patients and acamprosate is excreted unchanged in urine, acamprosate plasma concentrations are likely to be higher in the elderly population compared to younger adults.
                                                    <span class="Bold Italics">Age:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s44"></a><a name="section-11.3.2.3"></a><p></p>
<p class="First">The pharmacokinetics of Campral have not been evaluated in a pediatric population.
                                                    <span class="Bold Italics">Pediatrics:</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s45"></a><a name="section-11.3.2.4"></a><p></p>
<p class="First">:  Peak plasma concentrations after administration of a single dose of 2Â xÂ 333 mg Campral tablets to patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> were about 2-fold and 4-fold higher, respectively, compared to healthy subjects.  Similarly, elimination half-life was about 1.8-fold and 2.6-fold longer, respectively, compared to healthy subjects.  There is a linear relationship between creatinine clearance values and total apparent plasma clearance, renal clearance and plasma half-life of acamprosate.  A dose of 1Â xÂ 333Â mg Campral, three times daily, is recommended in patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of 30-50 mL/min, [ ].
                                                    <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span><span class="Italics">see Use in Specific Populations ( )
                                                        <a href="#s30">8.6</a></span></p>
<p>Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance of â‰¤30 mL/min) [ and ].
                                                    <span class="Italics">see Dosage and Administration ( ), Contraindications ( ), Warnings and Precautions ( ),
                                                        <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s9">5.1</a></span><span class="Italics">Use in Specific Populations ( )
                                                        <a href="#s30">8.6</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s46"></a><a name="section-11.3.2.5"></a><p></p>
<p class="First">:  Acamprosate is not metabolized by the liver and the pharmacokinetics of Campral are not altered in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (groups A and B of the Child-Pugh classification).  No adjustment of dosage is recommended in such patients.
                                                    <span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s47"></a><a name="section-11.3.2.6"></a><p></p>
<p class="First">: A cross-study comparison of Campral at doses of 2Â xÂ 333 mg three times daily indicated similar pharmacokinetics between alcohol-dependent subjects and healthy subjects.
                                                    <span class="Bold Italics">Alcohol-dependent subjects</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s48"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<p>Acamprosate had no inducing potential on the cytochrome CYP1A2 and 3A4 systems, and inhibition studies suggest that acamprosate does not inhibit metabolism mediated by cytochrome CYP1A2, 2C9, 2C19, 2D6, 2E1, or 3A4.  The pharmacokinetics of Campral were unaffected when co-administered with alcohol, disulfiram or diazepam.  Similarly, the pharmacokinetics of ethanol, diazepam and nordiazepam, imipramine and desipramine, naltrexone and 6-beta naltrexol were unaffected following co-administration with Campral.  However, co-administration of Campral with naltrexone led to a 33% increase in the C and a 25% increase in the AUC of acamprosate.  No adjustment of dosage is recommended in such patients.
                                            <span class="Italics">in vitro</span><span class="Italics">in vivo</span><span class="Sub">max</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s49"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s50"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Dietary administration of acamprosate calcium for 2 years to Sprague-Dawley rats at doses of 25, 100 and 400 mg/kg/day (up to 3 times the maximum recommended human daily (MRHD) oral dose on an AUC basis) and CD-1 mice at doses of 400, 1200 and 3600 mg/kg/day (up to 25 times the MRHD on an AUC basis) showed no evidence of increased tumor incidence.</p>
<p>Acamprosate calcium was negative in all genetic toxicology studies conducted.  Acamprosate calcium demonstrated no evidence of genotoxicity in an bacterial reverse point mutation assay (Ames assay) or an mammalian cell gene mutation test using Chinese Hamster Lung V79 cells.  No clastogenicity was observed in an chromosomal aberration assay in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and no chromosomal damage detected in an mouse micronucleus assay.
                                    <span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vitro</span><span class="Italics">in vivo</span></p>
<p>Acamprosate calcium had no effect on fertility after treatment for 70 days prior to mating in male rats and for 14 days prior to mating, throughout mating, gestation and lactation in female rats at doses up to 1000 mg/kg/day (approximately 4 times the MRHD oral dose on a mg/m basis).  In mice, acamprosate calcium administered orally for 60 days prior to mating and throughout gestation in females at doses up to 2400 mg/kg/day (approximately 5 times the MRHD oral dose on a mg/m basis) had no effect on fertility.
                                    <span class="Sup">2</span><span class="Sup">2</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s51"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of Campral in the maintenance of abstinence was supported by three clinical studies involving a total of 998 patients who were administered at least one dose of Campral or placebo as an adjunct to psychosocial therapy.  Each study was a double-blind, placebo-controlled trial in alcohol-dependent patients who had undergone inpatient detoxification and were abstinent from alcohol on the day of randomization.  Study durations ranged from 90 days to 360 days.  Campral proved superior to placebo in maintaining abstinence, as indicated by a greater percentage of subjects being assessed as continuously abstinent throughout treatment.</p>
<p>In a fourth study, the efficacy of Campral was evaluated in alcoholics, including patients with a history of polysubstance abuse and patients who had not undergone detoxification and were not required to be abstinent at baseline.  This study failed to demonstrate superiority of Campral over placebo.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s52"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">NDC:68151-4760-0 in a PACKAGE of 1 TABLET, DELAYED RELEASES</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s53"></a><a name="section-14.1"></a><p></p>
<p class="First"><span class="Bold">Storage and Handling</span></p>
<p>Store at 25ÂºC (77ÂºF); excursions permitted to 15Âº to 30ÂºC (59Âº to 86ÂºF).</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s54"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s55"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Information for Patients</h2>
<p class="First">Physicians are advised to discuss the following issues with patients for whom they prescribe Campral.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s56"></a><a name="section-15.1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>A lower dose is recommended for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Campral is contraindicated in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatine clearance of â‰¤30 mL/min) [ ].
                                            <span class="Italics">see Dosage and Administration ( ), Contraindications ( ), Warnings and Precautions ( ) and Use in Specific Populations ( )
                                                <a href="#s3">2.1</a><a href="#s7">4.2</a><a href="#s9">5.1</a><a href="#s30">8.6</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s57"></a><a name="section-15.1.2"></a><p></p>
<p class="First"><span class="Bold">Suicidality and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></span></p>
<p>Families and caregivers of patients being treated with Campral should be alerted to the need to monitor patients for the emergence of symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or suicidality, and to report such symptoms to the patient's health care provider [ ].
                                            <span class="Italics">see Warnings and Precautions ( )
                                                <a href="#s10">5.2</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s58"></a><a name="section-15.1.3"></a><p></p>
<p class="First"><span class="Bold">Alcohol Withdrawal</span></p>
<p>Use of Campral does not eliminate or diminish withdrawal symptoms [ ].
                                            <span class="Italics">see Warnings and Precautions ( )
                                                <a href="#s11">5.3</a></span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s59"></a><a name="section-15.1.4"></a><p></p>
<p class="First"><span class="Bold">Pregnancy and Breast Feeding</span></p>
<ul class="Disc">
<li>Advise patients to notify their physician if they become pregnant or intend to become pregnant during therapy.</li>
<li>Advise patients to notify their physician if they are breast-feeding.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s60"></a><a name="section-15.1.5"></a><p></p>
<p class="First"><span class="Bold">Relapse to Drinking</span></p>
<ul class="Disc">
<li>Advise patients to continue Campral therapy as directed, even in the event of relapse and remind them to discuss any renewed drinking with their physicians.</li>
<li>Advise patients that Campral has been shown to help maintain abstinence only when used as a part of a treatment program that includes counseling and support.</li>
</ul>
<p>Manufactured by: Merck SantÃ© s.a.s. Subsidiary of Merck KGaA, Darmstadt, Germany 37, rue Saint-Romain 69008 LYON FRANCE
                                            <br><br><br><br></p>
<p>Manufactured for: Forest  Pharmaceuticals, Inc. Subsidiary of Forest Laboratories, Inc. St. Louis, MO 63045
                                            <br><br><br></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s61"></a><a name="section-16"></a><p></p>
<h1>Campral</h1>
<div class="Figure"><img alt="Label Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=fe6f754f-62b4-4c86-805d-221332409516&amp;name=68151-4760.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAMPRALÂ 		
					</strong><br><span class="contentTableReg">acamprosate calcium tablet, delayed release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:68151-4760(NDC:0456-3330)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>acamprosate calcium</strong> (acamprosate) </td>
<td class="formItem">acamprosate calcium</td>
<td class="formItem">333Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM SILICATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (WHITE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">333</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:68151-4760-0</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021431</td>
<td class="formItem">01/11/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Carilion Materials Management
							(079239644)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Carilion Materials Management (079239644)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Carilion Materials Management</td>
<td class="formItem"></td>
<td class="formItem">079239644</td>
<td class="formItem">REPACK(68151-4760)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>30799fb0-c3e1-4b6e-9b30-5f30409b2b6d</div>
<div>Set id: fe6f754f-62b4-4c86-805d-221332409516</div>
<div>Version: 2</div>
<div>Effective Time: 20120131</div>
</div>
</div>Â <div class="DistributorName">Carilion Materials Management</div></p>
</body></html>
